title: [Primary multiple neoplasm of the endometrium and adjuvant hormone therapy in patients with breast cancer].
abstract: The contribution made by adjuvant hormone therapy in the development of primary multiple endometrial adenocarcinoma (EA) in patients with breast tumors (BT) is not quite clear. The study was based on the data on 5,790 cases of BT treated at our Clinic and 4,447 females screened for hormone-dependent neoplasms. Patients with BT were found to be at high cumulative risk for endometrial carcinogenesis caused by general factors of risk and pathogenesis. The risk was particularly high in BT (stage 1) within 12 months after treatment. There was no correlation between tamoxifen treatment and significant increase in EA frequency. Promotion of tumor proliferation by tamoxifen was identified in endometrial tissue in 62 patients with BT. This may facilitate clinical manifestations of another latent EA in such patients. Dynamic surveillance of the endometrium and ovary should include ultrasonography of pelvic organs and cytologic examination (smears) of the ecto- and endocervix and endometrial aspiration biopsy.
authors.affiliation: Prof. N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
authors.forename: E V
authors.initials: EV
authors.lastname: Bakhidze
authors.forename: S Ia
authors.initials: SIa
authors.lastname: Maksimov
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Barash
authors.forename: L M
authors.initials: LM
authors.lastname: Berstein
authors.forename: V F
authors.initials: VF
authors.lastname: Semiglazov
authors.forename: E V
authors.initials: EV
authors.lastname: Sheĭko
authors.forename: V I
authors.initials: VI
authors.lastname: Novik
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D016889:Endometrial Neoplasms / Q000139:chemically induced*; D004965:Estrogen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D009378:Neoplasms, Multiple Primary / Q000139:chemically induced*; D012306:Risk; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D013629:Tamoxifen
vernacular_title: Pervichno-mnozhestvennyĭ rak èndometriia i ad'iuvantnaia gormonoterapiia u bol'nykh rakom molochnoĭ zhelezy.